• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can PET Diagnose Alzheimer’s?

Can PET Diagnose Alzheimer’s?

June 1, 2004
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

If you haven't had patients asking you to order them a PET scan to diagnose Alzheimer's disease yet, brace yourself. It's only a matter of time.

PET scanning for AD was recently endorsed by no less august a figure than Charlton Heston (of "Ben Hur," "Ten Commandments," and, less gloriously, "Bowling for Columbine" fame), who announced in 2002 that he had been diagnosed with AD. Heston had evidently been won over by the Academy of Molecular Imaging, a professional group that is boosting PET scanning with almost religious zeal. The actor's endorsement was accompanied by a press release quoting UCLA's Daniel Silverman's claim that PET decreases false AD diagnosis "by almost half," and that using PET would lead to a "62% decrease in avoidable months of nursing-home care and a 48% drop in unnecessary drug treatment."

With numbers like these, who wouldn't be sold on the technology?
Sure, they’re nifty; but do PET scans add real value to a competent clinical diagnosis?

While TCR hates to be a killjoy, the story on PET scanning for AD is quite a bit more complex than this. This article will guide you through this confusing landscape, and we will--sorry to say--be discussing such dreaded statistics as "sensitivity" and "specificity."

Studies have shown that a psychiatrist's conventional low-tech approach to diagnosing dementia is quite accurate. A clinical diagnosis of "possible or probable AD" has a sensitivity of about 90%, and a specificity of about 50% (for a review of these studies, see "Practice Parameter: Diagnosis of Dementia (An Evidence- Based Review)" Neurology 2001; 56:1143- 1153).

"Sensitivity" is defined as the proportion of true cases picked up by the diagnostic procedure. Thus, a 90% sensitivity means that you pick up most of the very few patients to go undiagnosed. “Specificity” is a measure of the precision of your diagnosis. A specificity of only 50% means that half of the patients you diagnose as having AD don't actually have it. You're being overly inclusive, and you generate a lot of "false positive" diagnoses.

Is this such a bad thing? Not necessarily. By far the majority of the patients you've falsely diagnosed with AD have some other form of dementia, usually vascular dementia, and often some mixture of AD, vascular dementia, and Lewy Body Disease (J Am Geriatr Soc 1999; 47:564-569). The evidence is increasingly clear that all such patients benefit from immediate treatment with cholinesterase inhibitors, so the false AD label is unlikely to harm them in any way.

Now, the question we have to ask about PET is: Does a $1,500 PET scan add anything of value over and above what we can accomplish with the conventional workup?

The largest study reported to date relevant to this question involved 284 patients who were PET-scanned as part of the evaluation of cognitive deficits between 1984 and 1998 (JAMA 2001; 286:2120-2127). At least two years of clinical follow-up was obtained (via chart review) on about half of these patients (the UCLA portion of the study); the other half were treated at other sites, both in and out of the U.S., and researchers obtained autopsy data on these patients.

A nuclear medicine specialist read all the scans (he was, of course, blinded to the eventual outcome) and divided them into two categories: 1. "progressive scans" (a scan indicating dementia of some type) and 2. "nonprogressive scans" (no abnormal findings or nonspecific findings such as generalized cerebral atrophy).

How good were these two categories at predicting subsequent decline and diagnosis? Let's look first at the 146 patients who were followed clinically at UCLA, and for whom we do not have autopsy data. Of these 146 patients, 86 of them subsequently experienced some type of dementia over an average of 3.2 years of follow-up. Researchers had correctly put 78 of those 86 PET scans in the "progressive" pile, for a diagnostic sensitivity of 91%. Thus, based on PET findings alone, 8 of 86 patients would have been falsely reassured that their memory would not get worse (i.e., false negative rate of 9%).

What about specificity? Of the 60 patients whose memory held steady over three years, PET correctly predicted 45 of them (specificity 45/60=75%). This means that 15 patients would have falsely been given the nasty news that the brain scan indicated that they had dementia (25% false positives). The autopsy portion of the study produced similar figures. At autopsy, 97 patients were diagnosed with AD. PET predicted 91/97 = 94% of these, and correctly predicted no AD in 30/41 = 73%.

So how do we interpret these figures? How likely is it that PET scan data added something of value to these patients’ subsequent management? Well, the patients who had true dementia would likely have been picked up by a standard clinical exam anyway (since the sensitivity is comparable to PET). Scan or no scan, they would have received a prescription for a cholinesterase inhibitor and been scheduled for follow-up in a month.

The patients whose scans accurately predicted lack of dementia could breathe a $1,500 sigh of relief. But we psychiatrists can produce that same sigh much more cheaply with a careful clinical exam.

Where PET scans caused problems was for those 15 "false positive" patients whose scans were read as indicating dementia but who turned out to be fine 3 years later. In clinical practice, patients whom we falsely label AD generally have another type of dementia, so the treatment they get is actually helpful, despite the misdiagnosis. But PET has a nasty habit of finding AD-like perfusion defects in cognitively normal people. Thus, PET risks causing a lot of normal patients to become extremely anxious, not to mention leading to unnecessary further workup and medication. So even though there are fewer false positive diagnoses with PET scan, they are clinically more significant.

It appears, then, that PET scans are not yet "ready for prime time," an opinion seconded by the Agency for Health Research Quality (AHQR), which just concluded that PET does not add significant information to a competent clinical exam (http://www.cms.hhs.gov/coverage/ download/ADTAFinalReport- 042904-2.pdf). This federal opinion constitutes a death knell for those seeking Medicare coverage for PET in evaluating AD.

It's too bad. Those images sure are pretty.

TCR VERDICT: PET Scans: Too Much Bad News for the Absent-Minded
General Psychiatry
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: June 1, 2004
    SUBSCRIBE NOW
    Table Of Contents
    The First MRI
    Dr. Darin Dougherty on Research in Neuroimaging
    Neuroanatomy: A Very Short Course
    Can PET Diagnose Alzheimer’s?
    Neuroimaging: A Primer
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.